Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (4587)	10/19/2000 10:38:06 PM
From: Don Miller	Respond to of 10280

I think this LLY move was a combination of the lesser of two evils, and a torpedo launched at generic fluoxetine. The same premise applies to SEPR when they think R-DDMS will be markedly superior in 2004. Ask yourself if 8X of the R- is bad, is 8X of the racemic worse, and was it ever tested at this level. If they now test it and find it is worse, has FDA permitted the correct racemic dosage? Should racemic be permitted at all, if equal or better alternatives are in the market?